Aurinia Pharmaceuticals Inc. (AUPH)

NASDAQ: AUPH · IEX Real-Time Price · USD
5.78
+0.06 (1.05%)
At close: Mar 1, 2024, 4:00 PM
5.75
-0.03 (-0.52%)
After-hours: Mar 1, 2024, 7:41 PM EST
1.05%
Market Cap 835.89M
Revenue (ttm) 175.51M
Net Income (ttm) -78.02M
Shares Out 144.62M
EPS (ttm) -0.54
PE Ratio n/a
Forward PE 166.67
Dividend n/a
Ex-Dividend Date n/a
Volume 1,583,821
Open 5.75
Previous Close 5.72
Day's Range 5.64 - 5.88
52-Week Range 5.35 - 12.43
Beta 1.46
Analysts Strong Buy
Price Target 10.33 (+78.72%)
Earnings Date Feb 15, 2024

About AUPH

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 26, 1999
Employees 300
Stock Exchange NASDAQ
Ticker Symbol AUPH
Full Company Profile

Financial Performance

In 2023, AUPH's revenue was $175.51 million, an increase of 30.95% compared to the previous year's $134.03 million. Losses were -$78.02 million, -27.88% less than in 2022.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for AUPH stock is "Strong Buy." The 12-month stock price forecast is $10.33, which is an increase of 78.72% from the latest price.

Price Target
$10.33
(78.72% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program.

3 days ago - Business Wire

Aurinia to Participate in Upcoming Investor Healthcare Conferences

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia to Participate in Upcoming Investor Healthcare Conferences.

5 days ago - Business Wire

Aurinia Pharmaceuticals shares plummet amid failed buyer hunt, 25% employee layoff plans

U.S.-listed shares of Aurinia Pharmaceuticals (AUPH.O) witnessed a significant downturn, plummeting 25% to $6 in pre-market trading. The pharmaceutical company announced the conclusion of its strategi...

17 days ago - Invezz

Aurinia to stop development of immunotherapies after strategic review

Aurinia Pharmaceuticals will stop research and development on its immunotherapies to focus on its kidney disease drug Lupkynis after failing to attract a formal buyout offer, the company said on Thurs...

17 days ago - Reuters

Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value

ROCKVILLE, Maryland & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today provided an update on its 2023 fourth quarter and full year busines...

17 days ago - Business Wire

Exclusive: Kidney drug developer Aurinia fails to clinch a sale, sources say

Aurinia Pharmaceuticals , the kidney therapies developer that was pushed by activist hedge fund MKT Capital to sell itself, failed to attract binding offers and will embark on share buybacks and cost ...

17 days ago - Reuters

Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024.

27 days ago - Business Wire

Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results.

2 months ago - Business Wire

Aurinia Submits IND Application to US Food & Drug Administration for AUR 200

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Submits IND Application to US Food & Drug Administration for AUR 200.

2 months ago - Business Wire

Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan.

3 months ago - Business Wire

Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with LN at ACR 2023.

4 months ago - Business Wire

Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis.

4 months ago - Business Wire

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--AURINIA PHARMACEUTICALS REPORTS THIRD QUARTER AND NINE MONTHS 2023 FINANCIAL AND OPERATIONAL RESULTS.

4 months ago - Business Wire

Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis.

4 months ago - Business Wire

CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023

EDMONTON, Alberta--(BUSINESS WIRE)--Note revised call-in number for participants 877-407-9170 / +1 201-493-6756 (Toll-free U.S. & Canada) The updated release reads: AURINIA PHARMACEUTICALS TO RELEASE ...

4 months ago - Business Wire

Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the third quarter of...

4 months ago - Business Wire

Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (“Aurinia” or the “Company”), a biopharmaceutical company committed to delivering therapeutics that change the trajectory...

5 months ago - Business Wire

Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital.

5 months ago - Business Wire

Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership.

6 months ago - Business Wire

Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three and six months ended June 30, 2023. Amounts ar...

7 months ago - Business Wire

Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023.

8 months ago - Business Wire

Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that full results from the Phase 3, double-blind, placebo-controlled AURORA 2 e...

8 months ago - Business Wire

MKT Capital Pleased with Aurinia's Commencement of a Strategic Review Process

CAYMAN ISLANDS--(BUSINESS WIRE)--MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), the beneficial owner of approximately 4.2% of the outstanding common shares of Aurinia Pharmace...

8 months ago - Business Wire

Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value.

8 months ago - Business Wire

Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy.

9 months ago - Business Wire